Matrixyl

✓Key benefits

📈What to expect

Based on community reports and published research. Individual results vary significantly.

💊Dosing protocols

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Overview

Matrixyl was developed by Sederma and is the trade name for palmitoyl pentapeptide-4 (pal-KTTKS). It belongs to a class called matrikines - small peptides derived from extracellular matrix proteins that act as signalling molecules for tissue repair. The parent sequence KTTKS is a fragment of collagen type I. When detected by fibroblasts, it signals that collagen has been degraded and triggers new collagen synthesis. A double-blind clinical study by Robinson et al. (2005) showed that 12 weeks of Matrixyl application reduced wrinkle depth by up to 27% and wrinkle volume by 36%, with efficacy comparable to retinol but without the irritation.

⚙️How it works

The KTTKS sequence mimics a collagen breakdown fragment. When fibroblasts detect this signal, they interpret it as evidence of matrix damage and upregulate production of collagen types I, III, and IV, fibronectin, and other extracellular matrix components. The palmitoyl (C16 fatty acid) chain enhances skin penetration by increasing lipophilicity. This mechanism is distinct from retinoids (which work via nuclear receptor activation) and copper peptides (which work via copper-dependent enzyme activation), making Matrixyl compatible and synergistic with both.

⚡Side effects

📅Research history

Clinical evidence

The landmark study by Robinson et al. (2005) compared Matrixyl to retinol in a double-blind trial. Matrixyl reduced wrinkle depth by 27% and wrinkle volume by 36% after 12 weeks, with comparable or superior results to retinol - critically, without the irritation, peeling, and photosensitivity that limit retinoid use. Subsequent studies confirmed that palmitoyl pentapeptide-4 stimulates collagen synthesis in human dermal fibroblasts at concentrations as low as 1 ppm, with dose-dependent increases in collagen I and fibronectin.

Matrixyl 3000 and beyond

Matrixyl 3000 is an updated formulation combining palmitoyl tripeptide-1 (a different matrikine) with palmitoyl tetrapeptide-7 (which reduces IL-6 and inflammation). This combination addresses both matrix repair and chronic inflammation - the 'inflammaging' component of skin aging. Many modern serums marketed as 'Matrixyl' contain the 3000 version. Both the original Matrixyl and Matrixyl 3000 have published efficacy data, making them among the most evidence-backed peptide ingredients in skincare.

References

1. [1]Robinson LR, et al. 'Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin.' International Journal of Cosmetic Science, 2005.
2. [2]Lintner K, et al. 'Stimulation of extracellular matrix components by a biomimetic pentapeptide.' Proceedings of the 21st IFSCC Congress, 2000.

Frequently asked questions

Related peptides